OTC · BRRGF
BerGenBio ASA
$97.09$0.00 (0.0%)
BerGenBio ASA’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
Loading market information…
OTC · PSCBF · USD
Stock price
Quote as of May 24, 2024, 01:44 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Pascal Biosciences Inc.’s quoted price sits in the upper half of its reported 52-week range, 26.67% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE COMPANY BEHIND THE TICKER
Pascal Biosciences Inc. is an innovative biopharmaceutical firm dedicated to discovering and advancing therapeutic solutions for oncology and bolstering immune system function. The company's robust pipeline includes several key candidates: PAS-403, a potent mitosis inhibitor designed to impede cancerous cell division, specifically targeting glioblastoma and secondary brain tumors; and PAS-393, an immunomodulatory cannabinoid developed to enhance the immune system's recognition of tumor cells when utilized alongside checkpoint inhibitor therapy. Furthermore, Pascal is progressing a specialized antibody therapy aimed at B-cells, intended for conditions like acute lymphoblastic leukemia and various B-cell lymphomas. The company is also investigating cannabinoid-derived products as potential treatments for COVID-19. To support its research, Pascal Biosciences maintains an exclusive licensing agreement with the University of Washington for a cannabinoid-based therapeutic against glioblastoma multiforme and brain metastases. It also benefits from a collaborative research partnership with SoRSE Technology Corporation, focused on advancing PAS-393 toward clinical trials. Founded in 2011, the company operates from its headquarters in Seattle, Washington.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 01:17 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$97.09$0.00 (0.0%)
BerGenBio ASA’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
A$0.02-A$0.00 (-4.76%)
Epsilon Healthcare Limited’s quoted price sits in the lower half of its reported 52-week range, 50.0% below the high.
$0.06+$0.01 (+32.24%)
Tryp Therapeutics Inc.’s quoted price sits in the upper half of its reported 52-week range, 38.85% below the high.
$0.15$0.00 (0.0%)
Intellipharmaceutics International Inc.: Healthcare · Biotechnology.
$1.50$0.00 (0.0%)
Pixium Vision S.A.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
$0.00+$0.00 (+9,900.0%)
Invictus MD Strategies Corp.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
$3.25+$0.03 (+0.93%)
Guardion Health Sciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 81.94% below the high.
$0.04$0.00 (0.0%)
Field Trip Health & Wellness Ltd.’s quoted price sits in the lower half of its reported 52-week range, 91.76% below the high.
